FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2056712783> ?p ?o ?g. }

• W2056712783 endingPage "205" @default.
• W2056712783 startingPage "199" @default.
• W2056712783 abstract "Objective Effective therapies with a low rate of side effects are warranted in the 2nd-line setting in ovarian cancer. Both topotecan and the alkylating agent treosulfan have demonstrated efficacy in this patient group and are broadly used in Germany. Therefore, we started a prospectively randomized phase III trial comparing these two drugs in early recurrent ovarian cancer. Methods Patients having relapsed after platinum–taxane therapy were randomized to receive either topotecan or treosulfan. Stratification depended on platinum sensitivity (stratum 1: up to 6 months after primary chemotherapy, stratum 2: 6 to 12 months). Results A total of 274 patients were treated either with topotecan (136 patients) or treosulfan (138). Hematologic toxicity was significantly more frequent with topotecan but without severe clinical consequences. Non hematologic toxicity was similar in both study arms. Overall survival was significantly longer with topotecan (p=0.0023), with a median of 55.0 weeks versus 41.0 weeks as well as progression-free survival (p=0.0020) with a median of 23.1 weeks versus 12.7 weeks. Similar results were found for stratum 2 subgroup. Overall response rate was 27.5% for topotecan and 16.0% for treosulfan (p=0.0307). In stratum 1 progression-free survival was 18.1 weeks for topotecan and 9.4 weeks for treosulfan (p=0.0476), but there was no difference in overall survival in this prognostic poor subgroup. Conclusions This randomized phase III trial could detect superiority of topotecan versus treosulfan in patients with recurrent disease after platinum–paclitaxel combination therapy. Our experience indicates that optimization of systemic treatment could improve outcome even in this poor prognostic subgroup of patients with relapsed ovarian cancer." @default.
• W2056712783 created "2016-06-24" @default.
• W2056712783 creator A5020322058 @default.
• W2056712783 creator A5037650974 @default.
• W2056712783 creator A5047695952 @default.
• W2056712783 creator A5052434013 @default.
• W2056712783 creator A5064130922 @default.
• W2056712783 creator A5066710773 @default.
• W2056712783 creator A5068199769 @default.
• W2056712783 creator A5070536510 @default.
• W2056712783 creator A5084392138 @default.
• W2056712783 creator A5086907081 @default.
• W2056712783 date "2009-08-01" @default.
• W2056712783 modified "2023-10-16" @default.
• W2056712783 title "Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR)" @default.
• W2056712783 cites W1543697093 @default.
• W2056712783 cites W1831044128 @default.
• W2056712783 cites W1878670617 @default.
• W2056712783 cites W1905580151 @default.
• W2056712783 cites W1913802169 @default.
• W2056712783 cites W1943690049 @default.
• W2056712783 cites W1945760023 @default.
• W2056712783 cites W1960327677 @default.
• W2056712783 cites W1968367046 @default.
• W2056712783 cites W1970089830 @default.
• W2056712783 cites W1977093846 @default.
• W2056712783 cites W1980452371 @default.
• W2056712783 cites W1986575178 @default.
• W2056712783 cites W1986631637 @default.
• W2056712783 cites W1988643240 @default.
• W2056712783 cites W1989871857 @default.
• W2056712783 cites W2000963380 @default.
• W2056712783 cites W2001221382 @default.
• W2056712783 cites W2006350808 @default.
• W2056712783 cites W2006787885 @default.
• W2056712783 cites W2020482293 @default.
• W2056712783 cites W2025574413 @default.
• W2056712783 cites W2030144568 @default.
• W2056712783 cites W2032293229 @default.
• W2056712783 cites W2034509024 @default.
• W2056712783 cites W2048172660 @default.
• W2056712783 cites W2063318595 @default.
• W2056712783 cites W2071363801 @default.
• W2056712783 cites W2075668200 @default.
• W2056712783 cites W2076024279 @default.
• W2056712783 cites W2091111454 @default.
• W2056712783 cites W2092712722 @default.
• W2056712783 cites W2121129806 @default.
• W2056712783 cites W2121740300 @default.
• W2056712783 cites W2130941707 @default.
• W2056712783 cites W2133506440 @default.
• W2056712783 cites W2134947875 @default.
• W2056712783 cites W2137010750 @default.
• W2056712783 cites W2143219457 @default.
• W2056712783 cites W2151050516 @default.
• W2056712783 cites W2155126523 @default.
• W2056712783 cites W2282932528 @default.
• W2056712783 cites W2326952490 @default.
• W2056712783 cites W2328421677 @default.
• W2056712783 doi "https://doi.org/10.1016/j.ygyno.2009.04.026" @default.
• W2056712783 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19446314" @default.
• W2056712783 hasPublicationYear "2009" @default.
• W2056712783 type Work @default.
• W2056712783 sameAs 2056712783 @default.
• W2056712783 citedByCount "50" @default.
• W2056712783 countsByYear W20567127832012 @default.
• W2056712783 countsByYear W20567127832013 @default.
• W2056712783 countsByYear W20567127832014 @default.
• W2056712783 countsByYear W20567127832015 @default.
• W2056712783 countsByYear W20567127832016 @default.
• W2056712783 countsByYear W20567127832017 @default.
• W2056712783 countsByYear W20567127832018 @default.
• W2056712783 countsByYear W20567127832019 @default.
• W2056712783 countsByYear W20567127832020 @default.
• W2056712783 countsByYear W20567127832021 @default.
• W2056712783 countsByYear W20567127832023 @default.
• W2056712783 crossrefType "journal-article" @default.
• W2056712783 hasAuthorship W2056712783A5020322058 @default.
• W2056712783 hasAuthorship W2056712783A5037650974 @default.
• W2056712783 hasAuthorship W2056712783A5047695952 @default.
• W2056712783 hasAuthorship W2056712783A5052434013 @default.
• W2056712783 hasAuthorship W2056712783A5064130922 @default.
• W2056712783 hasAuthorship W2056712783A5066710773 @default.
• W2056712783 hasAuthorship W2056712783A5068199769 @default.
• W2056712783 hasAuthorship W2056712783A5070536510 @default.
• W2056712783 hasAuthorship W2056712783A5084392138 @default.
• W2056712783 hasAuthorship W2056712783A5086907081 @default.
• W2056712783 hasConcept C121608353 @default.
• W2056712783 hasConcept C126322002 @default.
• W2056712783 hasConcept C141071460 @default.
• W2056712783 hasConcept C143998085 @default.
• W2056712783 hasConcept C168563851 @default.
• W2056712783 hasConcept C2776694085 @default.
• W2056712783 hasConcept C2776755627 @default.
• W2056712783 hasConcept C2779178397 @default.
• W2056712783 hasConcept C2780427987 @default.
• W2056712783 hasConcept C2780611847 @default.
• W2056712783 hasConcept C2781209748 @default.

• next